Bringing a cancer medicine to patients -- from obtaining the materials and manufacturing it to a patient using it – represents a myriad of steps in which quality can be impacted. A panel of experts representing global manufacturers, healthcare professionals, policy makers and patients was convened last year by the Cancer Care Commission (CCC) and it identified key considerations for best ensuring quality medicines are made available to patients. The CCC turned these considerations into questions to which you can add your voice by participating in the CCC Quality Cancer Medicine Forum.
